Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van der Lee, I.
Right arrow Articles by Schramel, F. M. N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Lee, I.
Right arrow Articles by Schramel, F. M. N. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:557-561, 2001
© 2001 European Society for Medical Oncology

research-article

Single-agent gemcitabine in patients with resistant small-cell lung cancer

I. van der Lee1, E. F. Smit2, J. W. G. van Putten3, H. J. M. Groen3, N. J. J. Schlösser4, P. E. Postmus2 and F. M. N. H. Schramel1,

1Departments of Pulmonology, St Antonius Hospital Nieuwegein
2University Hospital, Vrije University Amsterdam
3University Hospital Groningen
4University Hospital Utrecht The Netherlands

Correspondence to: F M N H Schramel, MD, PhD, St Antonius Hospital P O Box 2500, 3430 EM Nieuwegein, The Netherlands E- mail antolong{at}knmg.nl

Objective This study was conducted to assess the activity and toxicity of gemcitabine in patients with resistant small-cell lung cancer (SCLC)

Patients and methods Forty-one patients with limited- or extensive-stage SCLC, who were previously treated with at least one chemotherapeutic regimen and progressed during or within three months of finishing the last regimen, were treated with 1000 mg/m2 gemcitabine on days 1, 8, and 15 of a four-week cycle.

Results Thirty-eight patients were evaluable for response Five partial and no complete responses were seen, for an overall response rate of 13% (95% confidence interval (Cl) 6%–27%) Time to progression varied from 4 to 20 weeks, with a median of 8 weeks Median survival was 17 weeks (range 4–84 weeks) Hematological toxicity mainly consisted of NCI-CTC grade 3 thrombocytopenia (29% of patients) and, to a lesser extent, grade 3 leukopenia (18% of patients) Non-hematological toxicity was mild, with nausea being the most commonly reported event

Conclusions Gemcitabine has modest activity in patients with resistant SCLC There is some non-cross resistance to most agents against SCLC

gemcitabine, resistant, small-cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. Inoue, S. Sugawara, K. Yamazaki, M. Maemondo, T. Suzuki, K. Gomi, S. Takanashi, C. Inoue, M. Inage, H. Yokouchi, et al.
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
J. Clin. Oncol., November 20, 2008; 26(33): 5401 - 5406.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Rocha-Lima, J. Herndon II, M. Lee, J. Atkins, A Mauer, E Vokes, M. Green, and For the Cancer and Leukemia Group B
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902
Ann. Onc., February 1, 2007; 18(2): 331 - 337.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Onoda, N. Masuda, T. Seto, K. Eguchi, Y. Takiguchi, H. Isobe, H. Okamoto, T. Ogura, A. Yokoyama, N. Seki, et al.
Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301
J. Clin. Oncol., December 1, 2006; 24(34): 5448 - 5453.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. A. Masters, L. Declerck, C. Blanke, A. Sandler, R. DeVore, K. Miller, and D. Johnson
Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597
J. Clin. Oncol., April 15, 2003; 21(8): 1550 - 1555.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.